A two-step purification platform for efficient removal of Fab-related impurities: A case study for Ranibizumab

Sadeleştirilmiş öğe sayfası
dc.contributor.authorTatli, Ozge
dc.contributor.authorOz, Yagmur
dc.contributor.authorDingiloglu, Baran
dc.contributor.authorYalcinkaya, Duygu
dc.contributor.authorBasturk, Ezgi
dc.contributor.authorKorkmaz, Melis
dc.contributor.authorAkbulut, Latif
dc.contributor.authorHatipoglu, Derya
dc.contributor.authorKirmacoglu, Cansin
dc.contributor.authorAkgun, Buse
dc.contributor.authorTurk, Kubra
dc.contributor.authorPinar, Orkun
dc.contributor.authorAkbulut, Berna Sariyar
dc.contributor.authorAtabay, Zeynep
dc.contributor.authorTuranli, Eda Tahir
dc.contributor.authorKazan, Dilek
dc.contributor.authorDoganay, Gizem Dinler
dc.date.accessioned2025-10-16T15:14:16Z
dc.date.issued2023
dc.identifier.doi10.1016/j.heliyon.2023.e21001
dc.identifier.otherWOS:001107794400001
dc.identifier.urihttps://openaccess.acibadem.edu.tr/handle/11443/6112
dc.publisherCELL PRESS
dc.sourceHELIYON
dc.subjectAntibody fragment
dc.subjectPharmaceutical purification
dc.subjectBiosimilar production
dc.subjectLiquid chromatography
dc.subjectMass spectrometry
dc.titleA two-step purification platform for efficient removal of Fab-related impurities: A case study for Ranibizumab
dc.typeArticle

Dosyalar

Koleksiyonlar

WOS